• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Antiplatelet Use in Ischemic Stroke
CONCLUSIONS: Although good evidence exists for the use of certain antiplatelet agents postischemic stroke, there are considerable opportunities for future research to investigate personalized therapies. These include screening patients for platelet polymorphisms that confer antiplatelet resistance and for randomized trials including more racially diverse populations.PMID:35094598 | DOI:10.1177/10600280211073009
Source: The Annals of Pharmacotherapy - January 31, 2022 Category: Drugs & Pharmacology Authors: Marharyta Kamarova Sheharyar Baig Hamish Patel Kimberley Monks Mohammed Wasay Ali Ali Jessica Redgrave Arshad Majid Simon M Bell Source Type: research

Vorapaxar in Atherosclerotic Disease Management.
CONCLUSION: Vorapaxar is approved for use with aspirin and/or clopidogrel in the secondary prevention of cardiovascular events in stable patients with peripheral arterial disease or a history of MI. However, the addition of vorapaxar to other antiplatelets can significantly increase the risk of bleeding. It is, therefore, essential to balance the need for further reduction of risk of thrombotic event with patient's individual bleeding risk. PMID: 25680760 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - February 13, 2015 Category: Drugs & Pharmacology Authors: Cheng JW, Colucci V, Howard PA, Nappi JM, Spinler SA Tags: Ann Pharmacother Source Type: research